Pricing Log in Create free account

CAMP4 Therapeutics Corporation (CAMP) vs Keros Therapeutics, Inc. (KROS)

CAMP4 Therapeutics Corporation and Keros Therapeutics, Inc. are both Biotechnology companies. CAMP4 Therapeutics Corporation and Keros Therapeutics, Inc. are of similar size ($220.1M and $216.5M). Keros Therapeutics, Inc. has the higher net margin (0.00% vs −2,543.7%) and the lower return on invested capital (−1,345.3% vs 0.00%). Across the 13 metrics below, Keros Therapeutics, Inc. leads on 11 and CAMP4 Therapeutics Corporation on 2.

Valuation

Metric CAMP KROS Biotechnology median
P/E n/m n/m 8.50
P/S 43.56 6.37 9.71
P/B n/m 0.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.46 0.64
EV/Sales 22.90 (1.39) 9.21
Earnings yield (73.19%) (34.64%) (33.15%)
Free cash flow yield (15.62%) (22.93%) (25.50%)

Profitability

Metric CAMP KROS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (1,254.22%) 0.00% 0.00%
Net margin (2,543.74%) 0.00% 0.00%
Free cash flow margin (680.36%) 0.00% 0.00%
Return on equity (545.85%) (17.16%) (56.36%)
Return on assets (148.23%) (15.92%) (48.04%)
Return on invested capital 0.00% (1,345.30%) 0.00%

Growth

Metric CAMP KROS Biotechnology median
Revenue growth (TTM) — (84.55%) 6.02%
EPS growth (last fiscal year) 76.00% 146.00% 30.26%
Revenue growth, 5-year CAGR — 89.45% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAMP KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.70 21.96 4.72
Net debt to EBITDA 2.18 (4.16) 0.96

Dividend

Metric CAMP KROS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CAMP KROS Biotechnology median
Market cap 216.50m 220.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack